Skip to content

The effect of erbium and SVF laser treatment in the treatment of striae

Comparison of the effect of combination Erbium YAG laser and SVF therapy with Erbium YAG laser alone in the treatment of striae

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200127046282N14
Enrollment
10
Registered
2022-05-02
Start date
2022-04-19
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

striae distensae. Atrophic disorder of skin, unspecified

Interventions

Intervention 1: Intervention group: Patients are injected with SVF cells isolated from adipose tissue with erbium YAG laser for 2 sessions with an interval of 1 month. Intervention 2: Control group: P

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Diagnosis of striae distensae based on the diagnosis of a dermatologist Patient satisfaction with the study Age less than 50 years and more than 18 years

Exclusion criteria

Exclusion criteria: Use any treatment to eliminate striae in the last three months Existence of skin lesions and diseases such as skin cancer wart Skin infection

Design outcomes

Primary

MeasureTime frame
Striae size. Timepoint: Before and 3 months after the intervention. Method of measurement: biometry.

Secondary

MeasureTime frame
Patient Satisfaction. Timepoint: Three months after treatment. Method of measurement: Questionnaire.;Pain. Timepoint: Injection time. Method of measurement: questionnaire.;Inflammation. Timepoint: 1-5 hours after injection. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Skin and Stem Cell Research Center, Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026